Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Ray-Coquard

Showing results (191-200 of 549) with videos related to

Pageof 55
Sort By:
Cancers|September 10, 2021
TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian CancerJulie Lecuelle, Romain Boidot, Hugo Mananet, et al.
Annales De Pathologie|August 1, 2025
[Optimal tissue quantity for molecular ancillary studies in multicenter clinical trials in gynecological oncology: Experience of the GINECO pathologists' group]Alexis Trecourt, Guillaume Bataillon, Isabelle Treilleux, et al.
Gynecologic Oncology|January 26, 2016
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabaseJacek P Grabowski, Philipp Harter, Florian Heitz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancerGiorgio Bogani, Robert L Coleman, Ignace Vergote, et al.
JCO Precision Oncology|August 10, 2023
<i>ESR1</i> Rearrangement as a Diagnostic and Predictive Biomarker in Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Report of Four CasesMarta Bini, Justine Gantzer, Armelle Dufresne, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 15, 2023
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancerGiorgio Bogani, Robert L Coleman, Ignace Vergote, et al.
European Journal of Cancer (Oxford, England : 1990)|May 13, 2026
COVID-19 vaccination before immune checkpoint inhibitor initiation and the overall survival of patients with advanced cancer: A cohort studyPierre-Etienne Heudel, Virginie Avrillon, Benedicte Mastroianni, et al.
Breast Cancer Research and Treatment|August 16, 2008
Prevalence of renal insufficiency in breast cancer patients and related pharmacological issuesVincent Launay-Vacher, Joseph Gligorov, Christophe Le Tourneau, et al.
Targeted Oncology|January 29, 2013
Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomasHiba el Sayadi, Daniel Pissaloux, Laurent Alberti, et al.
Gynecologic Oncology|October 26, 2013
Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO networkDenis Maillet, Thibaut Goulvent, Ruth Rimokh, et al.
Pageof 55

Showing results (191-200 of 549) with videos related to

Sort By:
Pageof 55
Cancers|September 10, 2021
TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian CancerJulie Lecuelle, Romain Boidot, Hugo Mananet, et al.
Annales De Pathologie|August 1, 2025
[Optimal tissue quantity for molecular ancillary studies in multicenter clinical trials in gynecological oncology: Experience of the GINECO pathologists' group]Alexis Trecourt, Guillaume Bataillon, Isabelle Treilleux, et al.
Gynecologic Oncology|January 26, 2016
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabaseJacek P Grabowski, Philipp Harter, Florian Heitz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancerGiorgio Bogani, Robert L Coleman, Ignace Vergote, et al.
JCO Precision Oncology|August 10, 2023
<i>ESR1</i> Rearrangement as a Diagnostic and Predictive Biomarker in Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Report of Four CasesMarta Bini, Justine Gantzer, Armelle Dufresne, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 15, 2023
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancerGiorgio Bogani, Robert L Coleman, Ignace Vergote, et al.
European Journal of Cancer (Oxford, England : 1990)|May 13, 2026
COVID-19 vaccination before immune checkpoint inhibitor initiation and the overall survival of patients with advanced cancer: A cohort studyPierre-Etienne Heudel, Virginie Avrillon, Benedicte Mastroianni, et al.
Breast Cancer Research and Treatment|August 16, 2008
Prevalence of renal insufficiency in breast cancer patients and related pharmacological issuesVincent Launay-Vacher, Joseph Gligorov, Christophe Le Tourneau, et al.
Targeted Oncology|January 29, 2013
Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomasHiba el Sayadi, Daniel Pissaloux, Laurent Alberti, et al.
Gynecologic Oncology|October 26, 2013
Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO networkDenis Maillet, Thibaut Goulvent, Ruth Rimokh, et al.
Pageof 55